Search clinical trials for: Pegylated liposomal doxorubicin

Total 3373 results

Haider Mahdi
Merck Sharp & Dohme LLC; ALX Oncology

Recruiting

Safety and Efficacy of Anti-CD47, ALX148 in Combination With Liposomal Doxorubicin and Pembrolizumab in Recurrent Platinum-resistant Ovarian Cancer

Ovarian Cancer

United States
UNC Lineberger Comprehensive Cancer Center
Merck Sharp & Dohme LLC; Millennium Pharmaceuticals, Inc.; Ortho Biotech, Inc.

Terminated

Vorinostat, Bortezomib, and Doxorubicin Hydrochloride Liposome in Treating Patients With Relapsed or Refractory Multiple Myeloma

Multiple Myeloma and Plasma Cell Neoplasm

United States
NYU Langone Health
National Cancer Institute (NCI)

Completed

Combination Chemotherapy in Treating Patients With Endometrial Cancer, Fallopian Tube Cancer, or Sarcoma of the Female Reproductive Tract

Sarcoma | Ovarian Cancer | Fallopian Tube Cancer | Endometrial Cancer

United States
Catharina Ziekenhuis Eindhoven
Sanofi; Cephalon

Completed

Liposomal Doxorubicin and Docetaxel in HER2 Negative Metastatic Breast Cancer (MYOTAX)

Breast Cancer | Neoplasm Metastasis

Netherlands
Roswell Park Cancer Institute
National Cancer Institute (NCI)

Terminated

Pegylated Liposomal Doxorubicin and Docetaxel in Treating Women With Locally Advanced Breast Cancer That Can Be Removed By Surgery

Breast Cancer

United States
Shanghai General Hospital, Shanghai Jiao Tong University...

Recruiting

The Effectiveness and Safety of XELOX and Tislelizumab + PLD for Resectable Gastric Cancer (LidingStudy)

Gastric Cancer

China
Fudan University

Recruiting

The Combination of Radiotherapy, Chemotherapy and Immunotherapy in High-Risk Localized Soft Tissue Sarcoma (RAPID)

High-Risk Localized Soft Tissue Sarcoma

China
Ludwig Institute for Cancer Research
Celgene; Cancer Research Institute, New York City; MedImmune LLC

Completed

Phase 1/2 Study of Motolimod, Doxorubicin, and Durvalumab in Recurrent, Platinum-Resistant Ovarian Cancer

Ovarian Cancer

United States, Switzerland
ARCAGY/ GINECO GROUP
European Organisation for Research and Treatment of Cancer - EORTC; Scherin... and other collaborators

Completed

Caelyx Plus Carboplatin Versus Paclitaxel Plus Carboplatin in Patients With Epithelial Ovarian Cancer in Late Relapse (CALYPSO)

Ovarian Cancer | Fallopian Tube Cancer

France
Gynecologic Oncology Group
National Cancer Institute (NCI)

Completed

Combination Chemotherapy in Treating Patients With Untreated Ovarian, Peritoneal, or Fallopian Tube Cancer

Ovarian Cancer | Fallopian Tube Cancer | Primary Peritoneal Cavity Cancer

United States, Norway
Merck Sharp & Dohme LLC
MDS Pharma Services

Completed

A Study to Determine the Activity of Caelyx With Trastuzumab and Docetaxel in the Treatment of Metastatic Breast Cancer (Study P03679)

Breast Neoplasm
Aptium Oncology Research Network
Ortho Biotech Products, L.P.

Unknown

Phase II Study in Patients With Operable Breast Cancer

Breast Cancer

United States
Bayer

Completed

Phase Ib Study of Anetumab Ravtansine in Combination With Pegylated Liposomal Doxorubicin in Patients With Recurrent Mesothelin-expressing Platinum-resistant Cancer

Ovarian Neoplasms

Belgium, Spain, Moldova, Republic of, United States
Sun Yat-sen University

Unknown

DCV in the Treatment of Recurrence and Refractory Childhood Solid Tumors

Unrecognized Condition
Fox Chase Cancer Center

Completed

A Study of Carboplatin, PLD and Everolimus in Certain Gynecologic Cancer

Fallopian Tube Cancer | Peritoneal Cavity Cancer | Recurrent Ovarian Epithelial Cancer

United States
National Cancer Institute (NCI)

Completed

Combination Chemotherapy With or Without Trastuzumab in Treating Women With Metastatic Breast Cancer

Stage IV Breast Cancer | Recurrent Breast Cancer

United States
Tianjin Medical University Cancer Institute and...

Unknown

Mutation Scores and Differential Protein Evaluating Efficacy in Adjuvant Chemotherapy in HER2(-) Luminal B Breast Cancer

Chemotherapy Effect | Susceptibility, Genetic

China
National Cancer Institute (NCI)
NRG Oncology

Completed

Pegylated Liposomal Doxorubicin Hydrochloride, Carboplatin, Veliparib, and Bevacizumab in Treating Patients With Recurrent Ovarian Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer

Recurrent Fallopian Tube Carcinoma | Recurrent Ovarian Carcinoma | Recurrent Primary Peritoneal Carcinoma | Ovarian Clear Cell Cystadenocarcinoma | Ovarian Endometrioid Adenocarcinoma | Ovarian Seromucinous Carcinoma | Ovarian Serous Cystadenocarcinoma | Undifferentiated Ovarian Carcinoma

United States
Merck Sharp & Dohme LLC

Completed

Caelyx in Ovarian Cancer: Prevention and Treatment of Infusion Reactions and Palmar-plantar Erythrodysesthesia (Study P04085)(COMPLETED)

Ovarian Neoplasms
University of Southern California

Terminated

Pegylated Liposomal Doxorubicin (Doxil) With Rituximab in Relapsed AIDS-Related Non-Hodgkin's Lymphomas

Non-Hodgkin's Lymphoma | Burkitt Lymphoma | Primary Effusion Lymphomas

United States
Pharmatech Oncology

Unknown

Liposomal Doxorubicin and Gemcitabine in Treating Women With Metastatic Breast Cancer

Breast Cancer

United States
Mayo Clinic
National Cancer Institute (NCI)

Completed

Avatar-Directed Chemotherapy in Treating Patients With Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

Recurrent Fallopian Tube Carcinoma | Recurrent Ovarian Carcinoma | Recurrent Primary Peritoneal Carcinoma

United States
City of Hope Medical Center
National Cancer Institute (NCI)

Active, not recruiting

Surgery and Chemotherapy With or Without Chemotherapy After Surgery in Treating Patients With Ovarian, Fallopian Tube, Uterine, or Peritoneal Cancer

Recurrent Fallopian Tube Carcinoma | Recurrent Ovarian Carcinoma | Recurrent Primary Peritoneal Carcinoma | Recurrent Uterine Corpus Carcinoma | Stage III Fallopian Tube Cancer AJCC v7 | Stage III Ovarian Cancer AJCC v6 and v7 | Stage III Primary Peritoneal Cancer AJCC v7 | Stage III Uterine Corpus... and other conditions

United States
National Cancer Institute (NCI)
NRG Oncology

Withdrawn

Comparing Standard of Care Chemotherapy Treatment to the Combination of Copanlisib and Olaparib for Recurrent Platinum Resistant Ovarian Cancer That Has Progressed Through PARP Inhibitor Therapy

Recurrent Ovarian High Grade Serous Adenocarcinoma | Recurrent Platinum-Resistant Ovarian Carcinoma | Recurrent Fallopian Tube Endometrioid Adenocarcinoma | Recurrent Ovarian Endometrioid Adenocarcinoma | Recurrent Platinum-Resistant Fallopian Tube Carcinoma | Recurrent Platinum-Resistant Primary... and other conditions

United States
Roswell Park Cancer Institute
Ortho Biotech, Inc.

Completed

Rituximab and Liposomal Doxorubicin in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma

Lymphoma

United States
The University of Texas Health Science Center,...

Unknown

Whole Body Hyperthermia Combined With Chemotherapy in Treating Patients With Metastatic Breast, Ovarian, Endometrial, or Cervical Cancer

Cervical Cancer | Breast Cancer | Ovarian Cancer | Endometrial Cancer

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Completed

Gemcitabine and Liposomal Doxorubicin in Treating Women With Metastatic Breast Cancer

Breast Cancer

United States
King Faisal Specialist Hospital & Research Center

Completed

Multi-national, Randomized, Phase III, GCIG Intergroup Study Comparing Pegylated Liposomal Doxorubicin (CAELYX) and Carboplatin vs. Paclitaxel and Carboplatin in Patients With Epithelial Ovarian Cancer in Late Relapse. (CALYPSO)

Epithelial Ovarian Cancer
Women's Hospital School Of Medicine Zhejiang University

Active, not recruiting

Evaluation of PLD Combined With Carboplatin Versus Paclitaxel Plus Carboplatin in the First-line Treatment of Epithelial Ovarian Cancer

Efficacy and Safety

China
Konkuk University Medical Center
National Cancer Center, Korea; Samsung Medical Center; Asan Medical Center; Seoul... and other collaborators

Completed

Real-World Effectiveness of PLD in Platinum- Sensitive Recurrent Ovarian Cancer

Ovarian Carcinoma

Korea, Republic of
Laurence J.C. van Warmerdam
Sanofi; Cephalon

Terminated

Liposomal Doxorubicin, Trastuzumab, and Docetaxel in HER2 Positive Metastatic Breast Cancer (MYOHERTAX)

Breast Cancer | Neoplasm Metastasis

Netherlands
Marval Pharma Ltd.

Terminated

Single Dose Safety, Tolerability and Pharmacokinetic Study of NCTX in Healthy Volunteers

Healthy Volunteers

United States
Gynecologic Oncology Group
National Cancer Institute (NCI)

Completed

TLR8 Agonist VTX-2337 and Pegylated Liposomal Doxorubicin Hydrochloride or Paclitaxel in Treating Patients With Recurrent or Persistent Ovarian Epithelial, Fallopian Tube, or Peritoneal Cavity Cancer

Recurrent Fallopian Tube Carcinoma | Recurrent Ovarian Carcinoma | Recurrent Primary Peritoneal Carcinoma | Ovarian Clear Cell Cystadenocarcinoma | Ovarian Endometrioid Adenocarcinoma | Ovarian Serous Cystadenocarcinoma | Malignant Ovarian Mixed Epithelial Tumor | Ovarian Brenner Tumor | Ovarian Mucinous... and other conditions

United States
National Cancer Institute (NCI)

Recruiting

Durvalumab in Combination With Chemotherapy in Treating Patients With Advanced Solid Tumors, (DURVA+ Study)

Malignant Solid Neoplasm

United States
Vanderbilt-Ingram Cancer Center
National Cancer Institute (NCI)

Terminated

Ph II Atrasentan + DOXIL in Recurrent Ovarian/Fallopian/Peritoneal Serous Papillary Adenocarcinoma

Ovarian Cancer | Fallopian Tube Cancer | Peritoneal Cavity Cancer

United States
Aravive, Inc.

Completed

Efficacy and Safety Study of AVB-S6-500 in Patients With Platinum-Resistant Recurrent Ovarian Cancer

Ovarian Cancer

United States
National Cheng-Kung University Hospital

Completed

Trial of Trientine Plus Pegylated Liposomal Doxorubicin and Carboplatin in Epithelial Ovarian Cancer (Trientine)

Fallopian Tube Cancer | Peritoneal Carcinoma | Ovarian Neoplasms Malignant (Excl Germ Cell)
Washington University School of Medicine

Completed

Phase I Study of DOXIL and Temsirolimus in Resistant Solid Malignancies

Resistant Solid Malignancies

United States
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co...

Completed

Assess Bioequivalence of Two Formulations of Doxorubicin Hydrochloride Liposome in Female Patients With Ovarian Cancer

Ovarian Cancer

China
Fudan University

Recruiting

Sintilimab and Bevacizumab Biosimilar Combined With PLD in mTNBC

Breast Cancer

China
M.D. Anderson Cancer Center

Completed

Liposomal Doxorubicin, Bevacizumab, and Everolimus in Patients With Locally Advanced TNBC With Tumors Predicted Insensitive to Standard Chemotherapy; A Moonshot Initiative

Invasive Breast Carcinoma | Triple-Negative Breast Carcinoma

United States
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

Completed

A Bioequivalence Study of Doxorubicin Hydrochloride Liposome Injection

Bioequivalence

China
Shanghai Pudong Hospital
CSPC Ouyi Pharmaceutical Co., Ltd.

Recruiting

To Evaluate the Cardiac Safety of Pegylated Liposomal Doxorubicin Concurrently Plus Trastuzumab and Pertuzumab in the Adjuvant Setting for Early-stage HER-2-positive Breast Cancer: a Multicenter, Randomized Controlled Clinical Study (easy laugh)

Breast Cancer

China
Fudan University

Recruiting

Study on the Correlation Between Immunoglobulin and Liposomal Doxorubicin in Vivo

Advanced Malignant Tumors

China
Luye Pharma Group Ltd.

Completed

Comparing the Pharmacokinetic Profile of LY01612 and CAELYX® in Chinese Subjects With Advanced Breast Cancer

Advanced Breast Cancer

China
Dr. Reddy's Laboratories Limited

Completed

Bioequivalence Study of Doxorubicin Hydrochloride Liposome Injection

Ovarian Epithelial Cancer Recurrent

India
Novartis Pharmaceuticals

Active, not recruiting

Alpelisib Plus Olaparib in Platinum-resistant/Refractory, High-grade Serous Ovarian Cancer, With no Germline BRCA Mutation Detected

Ovarian Cancer

United States, Italy, United Kingdom, Malaysia, Taiwan, Turkey, Belgium, Canada, Spain, Singapore, Austria, Denmark, Korea, Republic of, Australia, China, France, Netherlands, Russian Federation, Germany, Argentina, Mexico, Finland, Portuga... and more
Gustave Roussy, Cancer Campus, Grand Paris

Active, not recruiting

Pembrolizumab in Combination With Bevacizumab and Pegylated Liposomal Doxorubicin in Patients With Ovarian Cancer (PEMBOV)

Ovarian Cancer

France
Peking Union Medical College
CSPC Ouyi Pharmaceutical Co., Ltd.

Unknown

Pegylated Liposomal Doxorubicin Plus Albumin-Bound Paclitaxel and Trastuzumab in HER-2 Positive Breast Cancer

Breast Cancer

China
Prof Dirk Elling

Completed

Primary Chemotherapy in Patients With HER2-positive Early Breast Cancer (LAPADO)

Breast Cancer

Germany

Search clinical trials for: Pegylated liposomal doxorubicin

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in France

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations